Involvement of Plasmatic Factors in the Peripheral Muscle Dysfunction of COPD Patients - In Vitro Study

NCT03197909 | Completed

• 1 other identifier: RECHMPL17_0210
• Study Type: observational
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic Obstructive Pulmonary Patients is a defined by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. It is associated with an atrophy of the skeletal muscle that impairs the patient's prognosis. The biological mechanisms of this muscle atrophy have not been elucidated, and the "spill-over theory" has recently emerged. Indeed, in COPD patients, the pulmonary inflammation is associated with a systemic low-grade inflammation, and the increased pro-inflamatory molelcules in the blood - which constitute the cellular micro-environement of the muscle fibre - could activate the mechanisms of the cell atrophy.

Conditions

Chronic Obstructive Pulmonary

Keywords

COPD (Chronic Obstructive Pulmonary Patients); Atrophy; cell cultur; systemic inflammation; Catabolism

Outcome Measures

Primary Outcomes (1)

• Myotube diameter of in vitro cultured myotubes

  Myotube diameter of in vitro cultured myotubes from healthy subjects, exposed to the serum of healthy controls and COPD patients

  6 days

Secondary Outcomes (1)

• Expression and translation of markers of

  6 days

Other Outcomes (1)

• Level of pro-Inflamatory markers

  6 days

Study Arms (2)

Healthy subjects

Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old

Other: Determination of pro-inflammatory plasma factors

COPD patients

Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old

Other: Determination of pro-inflammatory plasma factors

Interventions

Determination of pro-inflammatory plasma factors OTHER

Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old

COPD patients; Healthy subjects

Eligibility Criteria

• Age: 35 Years - 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Chronic Obstructive Pulmonary Patients

You may qualify if:

• to 85 years old
• COPD patients: association of symtoms (breathlessness, cough, sputum) and chronic exposure to inhalated risk factors (like tobacco smoke) and a FEV1/VC ratio \<70% assessed by a spirometry
• Healthy subjects: A sedentariness assessed by a Voorrips score \<9.4 and/or a report of \<150 min/week of moderate-to-vigorous physical activity

You may not qualify if:

• A recent COPD exacerbation (\< 4weeks)
• The decompensation of a comorbidity
• An antioxidant supplementation or medication
• A long-term systemic corticosteroid medication

Sponsors & Collaborators

• University Hospital, Montpellier: lead

Study Sites (1)

Uhmontpellier

Montpellier, 34290, France

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive; Atrophy

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Pathological Conditions, Anatomical

Study Officials

• Maurice HAYOT, MD, PhD

  University Hospital, Montpellier

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 21, 2017
• First Posted: June 23, 2017
• Study Start: July 6, 2017
• Primary Completion: December 31, 2018
• Study Completion: January 31, 2019
• Last Updated: April 18, 2019

Record last verified: 2018-09

Locations

FR (1)